Bio Green Med Solution (BGMS) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
14 Aug, 2026Executive summary
Shifted focus from biopharmaceuticals to fire safety products after acquiring Fitters Sdn. Bhd. in September 2025, now operating primarily in Malaysia.
Entered into a Business Combination Agreement in June 2026 to acquire Future NRG Sdn. Bhd., which would result in FNRG shareholders owning over 99% of the combined company if completed.
Raised $794,403 in June 2026 through a private placement of 1,103,338 common shares at $0.72 per share.
Declared and paid a quarterly cash dividend of $0.15 per share on 6% Convertible Exchangeable Preferred Stock.
Deconsolidated UK subsidiary Cyclacel Limited in January 2025, resulting in a $5.0 million gain from discontinued operations.
Financial highlights
Revenue for the six months ended June 30, 2026: $1.1 million, all from fire safety product sales.
Product revenue from fire safety equipment was $336,000 for Q2 2026.
Net loss for the six months ended June 30, 2026: $0.6 million, improved from $1.4 million loss in the prior year.
Net loss for Q2 2026 was $0.4 million, a significant improvement from $1.3 million in Q2 2025.
Gross margin for the six months ended June 30, 2026: approximately 20%; for Q2 2026: approximately 23%.
Cash and cash equivalents as of June 30, 2026: $3.8 million.
Accumulated deficit as of June 30, 2026: $455.0 million.
Outlook and guidance
Revenues from fire safety expected to grow modestly in the near term, with higher growth anticipated from data center expansion in Malaysia.
General and administrative expenses projected to decrease significantly in 2026 due to absence of prior year one-time costs.
Current cash resources are expected to fund planned expenditures into Q1 2027.
Company is seeking additional capital through equity financing or strategic transactions to address liquidity concerns.
Latest events from Bio Green Med Solution
- All proposals passed, directors re-elected, and quorum confirmed at the virtual annual meeting.BGMS
AGM 2026 - Q1 2026 fire safety revenue hit $0.8M, but future viability hinges on new funding.BGMS
Q1 2026 - Stockholders will vote virtually on director elections, auditor ratification, and executive pay approval.BGMS
Proxy filing - Shareholders will virtually vote on directors, auditor ratification, and executive pay, all recommended for approval.BGMS
Proxy filing - Net loss narrowed to $3.0 million in 2025 as fire safety revenue reached $0.7 million.BGMS
Q4 2025 - Stockholders will vote on key proposals that could shift control and restructure the company's capital.BGMS
Proxy Filing - Shareholders to vote on equity issuances, reverse split, and governance changes to secure funding.BGMS
Proxy Filing - FADRA demonstrates durable responses in biomarker-driven cancer trials; PLOGO reformulation underway.BGMS
H.C. Wainwright 26th Annual Global Investment Conference 2024 - Lower Q2 loss and R&D spend, but cash runway and compliance risks persist.BGMS
Q2 2024